Concerning treatment options, patients with HR + /HER2 + breast cancer held a climbing opportunity to receive locoregional therapeutics, such as surgery and radiotherapy, yet a less access to systemic delivery, which could be attributed to the distinctive disease factors of the two subgroups observed in the cancer course. Here, ERBB2 is linked to breast cancer.